Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

582
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
582
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

434
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
434
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

616
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
616

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pneumonia and in-hospital mortality in ANCA-associated vasculitis: a nationwide population-based registry study in Spain.

Rheumatology (Oxford, England)·2026
Same author

Exposure-response relationship between transportation noise and cardiovascular disease outcomes: a systematic review and meta-regression analysis.

Journal of exposure science & environmental epidemiology·2026
Same author

Lead-Attributable Cardiovascular Disease Burden: Global Burden of Disease Study 2023.

JAMA·2026
Same author

Increasing Hospitalizations for Wernicke Encephalopathy in Spain: A Nationwide Population-Based Study.

Journal of clinical medicine·2026
Same author

Alcohol-Related and Non-Alcohol-Related Wernicke Encephalopathy: A Systematic Review and Meta-Analysis of Epidemiology and Clinical Features.

Neuroepidemiology·2025
Same author

Health effects associated with consumption of processed meat, sugar-sweetened beverages and trans fatty acids: a Burden of Proof study.

Nature medicine·2025

Related Experiment Video

Updated: Mar 5, 2026

Renal Subcapsular Transplantation of 2'-Deoxyguanosine-Treated Murine Embryonic Thymus in Nude Mice
07:39

Renal Subcapsular Transplantation of 2'-Deoxyguanosine-Treated Murine Embryonic Thymus in Nude Mice

Published on: July 19, 2019

11.8K

Sirolimus on Gorham-Stout disease. Case report.

Vanessa García1, Gloria Alonso-Claudio1, M-Teresa Gómez-Hernández2

  • 1Departamento de Medicina Interna. Hospital Clínico Universitario de Salamanca. Salamanca. España.

Colombia Medica (Cali, Colombia)
|March 29, 2017
PubMed
Summary

Gorham-Stout disease (GSD), a rare bone disorder, can manifest with pleural effusion. Sirolimus treatment showed promising remission in a patient with this GSD presentation.

Keywords:
Pleural effusionosteolysis essential, metrorrhagia, sirolimus, Gorham-Stout disease, prognosis, rare diseases, cell proliferation.

More Related Videos

Murine Full-thickness Skin Transplantation
07:59

Murine Full-thickness Skin Transplantation

Published on: January 2, 2017

21.5K
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.3K

Related Experiment Videos

Last Updated: Mar 5, 2026

Renal Subcapsular Transplantation of 2'-Deoxyguanosine-Treated Murine Embryonic Thymus in Nude Mice
07:39

Renal Subcapsular Transplantation of 2'-Deoxyguanosine-Treated Murine Embryonic Thymus in Nude Mice

Published on: July 19, 2019

11.8K
Murine Full-thickness Skin Transplantation
07:59

Murine Full-thickness Skin Transplantation

Published on: January 2, 2017

21.5K
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.3K

Area of Science:

  • Oncology
  • Vascular Biology
  • Rare Diseases

Background:

  • Gorham-Stout disease (GSD) is a rare, idiopathic condition characterized by abnormal vascular proliferation leading to bone matrix destruction.
  • GSD commonly affects the bone but can present with extraskeletal manifestations.

Observation:

  • A 43-year-old woman presented with sternal pain, dyspnea, abdominal mass, and serous-hematic pleural effusion.
  • Imaging revealed lesions on the left ribs, confirmed by biopsy showing lymphatic vascular proliferation in chest wall bone tissue.

Findings:

  • Sirolimus treatment initially induced disease remission within one month.
  • Treatment discontinuation due to metrorrhagia led to symptom recurrence; re-initiation resulted in symptom disappearance within four weeks.

Implications:

  • This case highlights sirolimus as a potential therapeutic alternative for Gorham-Stout disease with pleural effusion.
  • Further research is warranted to establish sirolimus efficacy and safety in managing GSD complications.